1-(3-溴-苯基)-环丙烷甲腈 | 124276-83-1

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 环烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴-苯基)-环丙烷甲腈
• 英文名称: 1-(3-bromophenyl)cyclopropane-1-carbonitrile
• 英文别名: 1-(3-bromophenyl)cyclopropanecarbonitrile
• CAS: 124276-83-1
• 化学式: C₁₀H₈BrN
• mdl: MFCD07374414
• 分子量: 222.084
• InChiKey: VHNBUFCWKWBTIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  334.3±35.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P501,P261,P270,P271,P264,P280,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330,P302+P352+P312,P304+P340+P312
• 危险性描述：
  H302+H312+H332,H315,H319
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(3-Bromophenyl)cyclopropanecarbonitrile
Synonyms: 1-(3-Bromophenyl)-1-cyanocyclopropane,

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(3-Bromophenyl)cyclopropanecarbonitrile
CAS number: 124276-83-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8BrN
Molecular weight: 222.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-溴-苯基)-环丙烷甲腈 在 lithium hydroxide 作用下， 以 水 、 乙二醇 为溶剂， 反应 24.0h， 生成 1-(3-溴苯基)环丙烷羧酸
  参考文献：
  名称：

  手性双齿硼酸配体使环丙烷的铱催化对映选择性 C(sp3)-H 硼酸化成为可能

  摘要：

  我们在此报告了首次使用手性双齿硼酸配体对环丙烷甲酰胺进行 Ir 催化的对映选择性 C(sp3)-H 硼酸化。具有 α-季碳中心的多种底物可以在该反应中相容，以提供具有良好至优异对映选择性的 β-硼酸化产物。我们还证明，硼酸化产物可用作多功能前体，参与 CB 键的立体有择转化，包括合成生物活性化合物 Levomilnacipran。

  DOI：

  10.1021/jacs.9b04549
• 作为产物：
  描述：

  1-bromo-3-(cyclopropylidenemethyl)benzene 在 氯化镍二甲氧基乙烷 、 三乙胺 、 间氯过氧苯甲酸 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.25h， 生成 1-(3-溴-苯基)-环丙烷甲腈
  参考文献：
  名称：

  镍催化 Favorskii 型环丁酮肟酯重排为环丙烷甲腈

  摘要：

  开发了镍催化碱促进环丁酮肟酯重排为环丙烷甲腈的方法。环丁酮肟酯的开环发生在空间位阻较小的一侧。原位形成的碱促进的镍基环丁烷中间体被认为参与了产物的形成。

  DOI：

  10.1055/s-0039-1690872

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2013134562A1

  公开（公告）日：2013-09-12

  The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

  本发明涉及的化合物属于式(I)及其药学上可接受的盐，可用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式(I)化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARα拮抗剂的治疗有效量。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及一种预防急性和慢性骨髓性白血病以及其他癌症发作和/或复发的方法，包括给予选择性PPARα拮抗剂的治疗有效量。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE ET DE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005019161A1

  公开（公告）日：2005-03-03

  This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一类新颖的化合物，其由下述公式表示，其中G、E、E、n、R1、R2、R3和R4的含义如公式中所示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K、L、S和B的抑制剂。这些化合物可用于治疗那些指示抑制骨吸收的疾病，例如骨质疏松症。
• [EN] TRIAZOLE COMPOUNDS AS ANTIVIRALS<br/>[FR] COMPOSÉS TRIAZOLES EN TANT QU'ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014006066A1

  公开（公告）日：2014-01-09

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了公式I的化合物：其中公式I中的变量定义如本文所述。还公开了包含此类化合物的药物组合物以及使用公式I化合物预防或治疗HCV感染的方法。
• Synthesis of HIV NNRTI Doravirine Analogues via Visible-Light Photoredox Decarboxylative Cross-Coupling
  作者：Abdellatif ElMarrouni、Linda Suen、Cheng Wang、David Hunter、Helen Mitchell、Antonella Converso

  DOI：10.1055/s-0037-1610155

  日期：2018.8

  utilizing dual nickel and photoredox catalysis for rapid parallel synthesis of diverse C-ring analogues of the HIV NNRTI clinical candidate doravirine is developed and described herein. This protocol features an alkylation with readily available and inexpensive methyl bromoacetate followed by hydrolysis to prepare an advanced doravirine intermediate, which undergoes decarboxylative cross-coupling with a variety

  作为专题“现代耦合方法及其在综合中的战略应用”的一部分发布 抽象的 在本文中开发并描述了利用双镍和光氧化还原催化的AC（sp 2）-C（sp 3）脱羧交叉偶联反应，可快速平行合成HIV NNRTI临床候选药物Doravirine的各种C环类似物。该方案的特点是使用容易获得的廉价溴乙酸甲酯进行烷基化，然后水解以制备高级Doravirine中间体，该中间体与各种芳基和杂芳基溴化物进行脱羧交叉偶联。当前方法的温和性，广泛的适用性和可持续性是对先前报道的方法的改进，并允许快速并行合成类似物。报告了该方法的优化和范围。 在本文中开发并描述了利用双镍和光氧化还原催化的AC（sp 2）-C（sp 3）脱羧交叉偶联反应，可快速平行合成HIV NNRTI临床候选药物Doravirine的各种C环类似物。该方案的特点是使用容易获得的廉价溴乙酸甲酯进行烷基化，然后水解以制备高级Doravirine中间体，该中间
• Synthesis of ¹⁸ F-Difluoromethylarenes from Aryl (Pseudo) Halides
  作者：Hang Shi、Augustin Braun、Lu Wang、Steven H. Liang、Neil Vasdev、Tobias Ritter

  DOI：10.1002/anie.201604106

  日期：2016.8.26

  readily prepared from aryl chlorides, bromides, iodides, and triflates. Seven 18F‐difluoromethylarene drug analogues and radiopharmaceuticals including Claritin, fluoxetine (Prozac), and [18F]DAA1106 were synthesized to show the potential of the method for applications in PET radiopharmaceutical design.

  报道了用于放射性药物发现的从[ 18 F]氟化物合成[ 18 F]二氟甲基芳烃的通用方法。该方法实用、操作简单，可耐受多种官能团，并且能够标记各种芳烃和杂芳烃，放射化学产率（RCY，未衰变校正）为 10% 至 60%。18 F-氟化前体很容易由芳基氯、芳基溴化物、碘化物和三氟甲磺酸酯制备。合成了七种18 F-二氟甲基芳烃药物类似物和放射性药物，包括开瑞坦、氟西汀（百忧解）和 [ 18 F]DAA1106，以显示该方法在 PET 放射性药物设计中的应用潜力。